Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Celgene (NASDAQ:CELG) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Celgene's business and see what CAPS investors are saying about the stock right now.

Celgene facts 

Headquarters (founded)

Summit, N.J. (1980)

Market Cap

$17.92 billion



Trailing-12-Month Revenue

$2.25 billion


CEO Dr. Sol Barer (since 2006)
CFO David Gryska (since 2006)

Compound Annual Revenue Growth (over last five years)



Bristol-Myers Squibb (NYSE:BMY)

CAPS members bullish on CELG also bullish on

Johnson & Johnson (NYSE:JNJ)

CAPS members bearish on CELG also bearish on (NASDAQ:AMZN)
Research In Motion (NASDAQ:RIMM)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS.

Over on CAPS, fully 1,305 of the 1,365 members who have rated Celgene -- some 96% -- believe the stock will outperform the S&P 500 going forward. These bulls include All-Star Josher429, who is ranked in the top 10% of our community, and InvestorDeb.

In February, Josher429 listed several of Celgene's strong points: "Great earnings visibility, little competition for its three main drugs, lots of cash, and no [long-term] debt. What's not to like?"

In a pitch from two weeks ago, InvestorDeb cited Celgene's weak first-quarter outlook (and subsequent price plunge) as an opportunity for patient investors:

Celgene's long-term appeal has not changed: Revlimid is and will remain the drug of choice for multiple myeloma with massive growth potential ... as well as maintenance use. Revlimid is the safest, strongest drug out there with no competition. … The company's Vidaza drug (acquired by Pharmion) remains strong and will be more accretive to earnings over time simply due to its superior survival benefits and its exclusivity to the market outside the U.S. ...

The preannouncement was related to the slowing economy, which will impact most (if not all) companies. … Importantly, though, Celgene indicated that prescription trends were strong in January and February (and likely March but the quarter just closed) in both the U.S. and in Europe.

Cancer medicine is not something that people "do without" to save money.

What do you think about Celgene, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick, Google is a Rule Breakers recommendation, and Amazon is a selection of Stock Advisor. The Fool's disclosure policy always gets a perfect score.